Expanded access protocol


Advancing our commitment to patients living with lower risk MDS

The imetelstat expanded access protocol (EAP) is a U.S.-only protocol for eligible adult participants diagnosed with lower risk (very low, low, intermediate risk by IPSS-R) myelodysplastic syndromes (MDS) who are red blood cell (RBC) transfusion dependent, have failed to respond or have lost response or are ineligible for erythropoiesis-stimulating agents (ESAs), had not received prior treatment with either a hypomethylating agent or lenalidomide and were non-del(5q). Additional information to be available on www.clinicaltrials.gov.
 
U.S.-based healthcare professionals seeking more information about the imetelstat EAP can email GeronEAP@wepclinical.com.

Lower risk MDS patients who are interested in enrolling to the imetelstat EAP should speak with their physician to understand if imetelstat is an appropriate treatment option.